Anti-allergic and Profilaggrin (ProFLG)-mRNA expression modulatory effects of sacran

Int J Biol Macromol. 2017 Dec;105(Pt 2):1532-1538. doi: 10.1016/j.ijbiomac.2017.05.049. Epub 2017 May 15.

Abstract

Atopic dermatitis (AD) is a skin disorder characterized by filaggrin (FLG) defect. We evaluated sacran's effects on dust-mite extracts (DME)-induced AD-like disease and also its effect on profilaggrin (proFLG) in a murine model of 2,4-dinitroflurobenze (DNFB)-induced contact hypersensitivity. In the murine AD-like disease model, allergic NC/Nga mice (N=60) were randomly divided into five treatment groups of 12 animals each: 0.2% and 1%sacran; 0.1% Tacrolimus; Vaseline and buffer-treated controls. Blood samples were drawn and serum levels of representative Th-1, Th-2 and also Th-17 (IL-17A) cytokines were assayed by Cytometric Bead Array (CBA). In the contact hypersensitivity model, diseased NC/Nga mice (N=20) were divided into four groups of five mice each [0.05%sacran, 0.05% chondroitin sulfate (CS), 0.5% prednisolone (PD), non-treated control group] and were treated for 14days. Skin biopsies were performed for the measurement of proFLG-mRNA by real-time PCR. Sacran solutions and 0.1%Tacrolimus reduced disease severity, suppressed histological changes and decreased the serum Th-1 (IFN-γ, TNF-α, IL-2) and Th-2 (IL-4, IL-6, IL-10) cytokines in allergic mice (vs. controls). Additionally, a marked increase of proFLG-mRNA expression was observed in 0.05%sacran group (vs. control 0.05% CS and 0.5% PD groups). Thus, Sacran might be useful as a natural skin barrier enhancer and anti-allergic agent.

Keywords: Atopic dermatitis; Profilaggrin; Sacran.

MeSH terms

  • Administration, Topical
  • Animals
  • Anti-Allergic Agents / administration & dosage
  • Anti-Allergic Agents / pharmacology*
  • Anti-Allergic Agents / therapeutic use
  • Cytokines / blood
  • Dermatitis, Atopic / blood
  • Dermatitis, Atopic / drug therapy
  • Dermatitis, Atopic / genetics
  • Dermatitis, Atopic / immunology
  • Female
  • Filaggrin Proteins
  • Intermediate Filament Proteins / genetics*
  • Mice
  • Polysaccharides / administration & dosage
  • Polysaccharides / pharmacology*
  • Polysaccharides / therapeutic use
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Skin / drug effects
  • Skin / pathology
  • T-Lymphocytes, Helper-Inducer / drug effects
  • T-Lymphocytes, Helper-Inducer / metabolism
  • Up-Regulation / drug effects*

Substances

  • Anti-Allergic Agents
  • Cytokines
  • Filaggrin Proteins
  • Intermediate Filament Proteins
  • Polysaccharides
  • RNA, Messenger
  • sacran